Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Chemicals and Drugs

Edith Cowan University

Research outputs 2022 to 2026

COVID-19

Articles 1 - 1 of 1

Full-Text Articles in Medicine and Health Sciences

Early Th2 Inflammation In The Upper Respiratory Mucosa As A Predictor Of Severe Covid-19 And Modulation By Early Treatment With Inhaled Corticosteroids: A Mechanistic Analysis, Jonathan R. Baker, Mahdi Mahdi, Dan V. Nicolau, Sanjay Ramakrishnan, Peter J. Barnes, Jodie L. Simpson, Steven P. Cass, Richard E. K. Russell, Louise E. Donnelly, Mona Bafadhel Jun 2022

Early Th2 Inflammation In The Upper Respiratory Mucosa As A Predictor Of Severe Covid-19 And Modulation By Early Treatment With Inhaled Corticosteroids: A Mechanistic Analysis, Jonathan R. Baker, Mahdi Mahdi, Dan V. Nicolau, Sanjay Ramakrishnan, Peter J. Barnes, Jodie L. Simpson, Steven P. Cass, Richard E. K. Russell, Louise E. Donnelly, Mona Bafadhel

Research outputs 2022 to 2026

Background: Community-based clinical trials of the inhaled corticosteroid budesonide in early COVID-19 have shown improved patient outcomes. We aimed to understand the inflammatory mechanism of budesonide in the treatment of early COVID-19. Methods: The STOIC trial was a randomised, open label, parallel group, phase 2 clinical intervention trial where patients were randomly assigned (1:1) to receive usual care (as needed antipyretics were only available treatment) or inhaled budesonide at a dose of 800 μg twice a day plus usual care. For this experimental analysis, we investigated the nasal mucosal inflammatory response in patients recruited to the STOIC trial and in …